Form D · Pharmaceuticals
Biohaven Pharmaceutical Holding Co Ltd.
New Haven, CT · CIK 0001689813
Offering snapshot reported Nov 10, 2016 · SEC filing
- Reported sold
- $40M Offering amount: $80M
- Investors reported
- 34 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 31, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 10, 2016 | Initial | $40,000,127 | No comparison | 34 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $4.55M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-274252
Series A Preferred Shares
Commission paid in combination of equity issuance and cash payment
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Cowen and Company | 7616 | |
| William Blair | 1252 |
Source: Form D, filed Nov 10, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Greg Bailey | Director |
| Robert Berman, M.D. | Executive |
| John Childs | Director |
| Vladimir Coric, M.D. | Director, Executive |
| Declan Doogan | Director |
| Jim Engelhart | Executive |
| Kimberly Gentile | Executive |
| Kam Shah | Director |
| John Tilton | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
234 Church Street, Suite 304
New Haven, CT, 06510
New Haven, CT, 06510